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Background: An effective HIV vaccine is still elusive. Of the 9 HIV preventive vaccine efficacy trials conducted to-date,
only one reported positive results of modest efficacy. More efficacy trials need to be conducted before one or more
vaccines are eventually licensed. We assessed the suitability of fishing communities in Uganda for future HIV vaccine
efficacy trials.
Methods: A community-based cohort study was conducted among a random sample of 2191 participants aged 18–49
years. Data were collected on socio-demographic characteristics, HIV risky behaviors, and willingness to participate in
future HIV vaccine trials (WTP). Venous blood was collected for HIV serological testing. Retention/follow rates and HIV
incidence rates per 100 person years at-risk (pyar) were estimated. Adjusted prevalence proportion ratios (PPRs) of
retention and odds ratios (ORs) of lack of WTP were estimated using log-binomial and logistic regression models
respectively.
Results: Overall retention rate was 76.9% (1685/2191), highest (89%) among participants who had spent 5+ years in
the community and lowest (54.1%) among those with <1 year stay. Significant predictors of retention included tribe/
ethnicity, baseline HIV negative status, and longer than 1 year stay in the community. Overall WTP was 89.1% (1953/
2191). Lack of WTP was significantly higher among women than men [adj.OR = 1.51 (95% CI, 1.14- 2.00)] and among
participants who had stayed in fishing communities for 10 or more years relative to those with less than one year
[adj.OR = 1.78 (95% CI, 1.11 - 2.88)]. Overall HIV incidence rate per 100 pyar was 3.39 (95% CI; 2.55 - 4.49). Participants
aged 25–29 years had highest incidence rates (4.61 - 7.67/100 pyar) and high retention rates between 78.5 and 83.1%.
In a combined analysis of retention and incidence rates participants aged 30+ years had retention rates ~80% but low
incidence rates (2.45 - 3.57 per 100 pyar) while those aged 25–29 years had the highest incidence rates (4.61 - 7.67/100
pyar) and retention rates 78.5 - 83.1%.
Conclusions: There is high HIV incidence, retention and WTP among fishing communities around L. Victoria, Uganda
which make these communities appropriate for future HIV prevention efficacy studies including vaccine trials.
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Despite the current proven methods of HIV prevention
[1-10], an estimated 2.3 million people worldwide become
newly infected with HIV each year. The number of new
HIV infections has decreased but is still higher than the
number of patients initiating Antiretroviral Therapy (ART)
[11]. The development of a safe, effective, and accessible
HIV preventive vaccine will greatly complement the
current prevention interventions and probably lead to the
ultimate control of the HIV pandemic. The discovery of an
effective HIV vaccine has multiple challenges including the
extensive variability of the virus, an incomplete under-
standing of the mechanisms for immune protection, and
the need to identify and characterize appropriate popula-
tions for efficacy clinical trials. One of the critical elements
of an HIV vaccine efficacy trials is the identification of pop-
ulations with adequate rates of new HIV infections who
are willing to participate (WTP) and who can be efficiently
recruited and retained for the duration of the vaccine trial
[12,13].
To date, a few efficacy trials of HIV preventive vaccines
have been conducted predominantly in highly selected
populations [14-19] and all but one [20] reported lack of
efficacy in protecting against HIV infection. Since an effect-
ive HIV vaccine still eludes the world, more efficacy trials
will need to be conducted before licensure is attained.
With a number of HIV vaccine candidates currently under
phase I and II trials [21,22], it is prudent to identify and
prepare suitable populations for future efficacy trials. We
assessed the suitability of fishing communities along Lake
Victoria, Uganda, as a potential population for future HIV
vaccine efficacy trials. In Uganda, fishing communities
together with sex workers and long distance truck drivers
have been shown to have high incidence rates [23-27] that
are 3–7 times higher than the estimated national general
population rate [28]. The high risk profile of fishing
communities is attributed to a number of factors including
the mobile lifestyle of fishermen [27,29-31], high concen-
tration of drinking and entertainment places, high levels al-
cohol consumption, transactional sex, multiple sexual
partnerships and limited access to prevention and care
services [24,27,32-34].
Methods
Study population and procedures
Between September 2011 and March 2013, we con-
ducted a community-based cohort study among adults
in 8 fishing communities (1 lakeshore and 7 islands) in 3
districts bordering Lake Victoria in central Uganda, a re-
gion that is mainly inhabited by people of Baganda tribe/
ethnicity. Detailed study procedures have been previ-
ously described [35] but briefly, a random sample of
2200 participants aged 18–49 years resident in fishing
communities for at least 6 months prior to baselineenrolment were selected from a community wide census
database using Stata® 12 (StataCorp, College Station, TX)
software. Of the 2200 selected, 2191 provided written in-
formed consent and were enrolled at baseline. Interviewer-
administered semi-structured questionnaires were used to
collect data on socio-demographic characteristics, HIV risk
behaviours, and willingness to participate (WTP) in future
HIV vaccine studies. Over 99% of the questionnaires were
administered in Luganda (the most commonly spoken
language in the study communities) while others were in
English. Two weeks to one month prior to the scheduled
follow up visit date, community-based health education
meetings were conducted, attended by both participants
and non-participants. In addition to education and infor-
mation sharing, participants were reminded of the impend-
ing follow up visit but no individualized contact, mailings,
phone calls or written invitations were provided. At each
visit, venous blood was collected for HIV-1 serological test-
ing and participants were given free voluntary counseling
and testing by certified HIV counselors. HIV infected par-
ticipants were referred to HIV/AIDS care centres for fur-
ther management and encouraged to seek care. Individuals
in study communities (participants and non-participants)
were given free access to HIV prevention services includ-
ing health education, counseling, treatment of sexually
transmitted infections (STIs) and voluntary medical male
circumcision. After completion of the study procedures
each study participant was reimbursed 5000 Uganda shil-
lings (2 USD) for time and travel. Institutional Review
Board approvals were obtained from the Uganda Virus Re-
search Institute’s Science and Ethics Committee and the
Uganda National Council for Science and Technology.
Laboratory testing
HIV-1 status was determined by rapid HIV tests
performed in the community by certified laboratory tech-
nologists and EIA confirmation in the laboratory at
Uganda Virus Research Institute. In the rapid HIV testing
algorithm blood samples were first tested with Determine®
HIV assay (Alere Medical Co., Ltd., Chiba, Japan), and if
negative, results were reported as negative. Determine®
positive samples were then tested with HIV 1/2 Stat-Pak®
assay (Chembio Diagnostic Systems, Inc. Medford, NY,
USA), if positive, results were reported as positive. But if
negative on Stat-Pak®, Uni-Gold™ HIV test (Trinity
Biotech plc, Bray, Ireland) was used as a tie-breaker. All
positive rapid results were confirmed using 2 parallel
Enzyme Linked Immuno Sorbent Assay (EIA) tests:
Vironostika (HIV Uni-Form II plus 0 microelisa system,
Biomerieux, SA, Marcy l’Etoile, France); and Murex HIV-
1.2.O (Diasorin S.P.A, Dartford, United Kingdom).
Concordant EIA positives were taken as positive but
discordant EIA results were comfirmed using HIV RNA
PCR (COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test,
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Statistical analysis
To evaluate the suitability of fishing communities as po-
tential populations for future HIV prevention efficacy
studies, we assessed absolute HIV incidence, retention
and WTP. HIV incidence rates per 100 person years at-
risk (pyar) were estimated among initially seronegative
participants as the number of seroconversions divided
by pyar multiplied by 100. HIV infection was estimated
to have occurred at the midpoint between the last nega-
tive and first positive serologic tests. Retention was cal-
culated as the number of participants traced and
interviewed at the 12 months visit divided by the num-
ber enrolled at baseline. Given the high proportion of
retention/follow up (76.9%) we used log-binomial reg-
ression models to estimate unadjusted and adjusted
prevalence proportion ratios (PPRs) and corresponding
95% CIs of factors associated with retention. Since odds
ratios give biased estimates of prevalence ratios when
the proportion of the outcome is greater than 10%, we
used log binomial regression instead of logistic regres-
sion [36,37]. The final model on retention included gen-
der, age, tribe, occupation, marital status, and duration
of stay in community. WTP was assessed hypothetically
given that the study did not involve recruitment and re-
ceipt of a vaccine (experimental or licensed). This was
done only at the baseline visit and the specific question
on WTP was: If you were requested to participate in a
research study on an experimental HIV preventive vac-
cine, would you be willing to join the study as a partici-
pant? The responses were willing, not willing, not sure,
partner would decide and parent would decide. Only the
first 3 got responses and the covariate was dichotomized
into willing and not willing; not willing and not sure
combined because the frequency of the latter was too
small for meaningful analyses. Since we were interested
in determining characteristics of fisherfolk that one
would address in preparation for efficacy trials of HIV
prevention, we modeled unwillingness to participate in
HIV vaccine trials as the outcome. With a prevalence of
10.7%, ordinary multivariable logistic regression models
were used to determine factors associated with unwill-
ingness to participate in vaccine trials. The final model
included sex, occupation, duration of stay in community,
and alcohol consumption. In all multivariable models we
used empirical variance estimator to estimate robust
standard errors accounting for any potential correlation
at household level (where more than 1 participant from
a given household were selected) [38]. Inclusion of vari-
ables in multivariable models was based on biological
plausibility and a bivariate statistical significance at an
alpha (α) of <0.15 but statistical significance wasdetermined by α <0.05. All regression models were con-
structed using stepwise logical model building method
[39] and statistical analyses were performed using Stata®
12 (StataCorp, College Station, TX) software. Analyses
involved participants that were HIV negative at baseline
and hence at risk of infection.
Results
Participant retention
Table 1 shows absolute retention rates, and unadjusted
and adjusted prevalence ratios (PRs) of factors associated
with retention in fishing communities around Lake
Victoria, Uganda. Of the 2191 participants enrolled at
baseline, 1685 were interviewed at the 12 months visit
giving an overall retention rate of 76.9%. The highest
retention rate of 89% was seen in participants who had
spent 5 or more years in fishing communities. Retention
rates of 80% or more were observed in farming occupa-
tion (85.4%), Baganda tribe (80.9%), married monogam-
ous (80.5%), HIV negative at baseline (80.2%), and
being aged 30 or more years (80.6% for 30–39 years and
83.7% among 40–49 years). The lowest retention rate of
54.1% was observed among participants who at baseline
had spent less than a year in fishing communities. At bi-
variate analysis, retention was significantly lower among
participants aged 18–24 years, non-Baganda, bar/hotel/
restaurant workers, single never married, baseline HIV
positive, and those who had spent less than a year in the
fishing communities. Retention did not statistically differ
by sex, age, education status, or religion but adjusted
differences were observed according to ethnicity, marital
status, occupation, duration of stay in the community,
and baseline HIV sero-status (Table 1). Retention was
significantly higher among the Baganda ethnic group
(adj.PPR = 1.07; 95% CI, 1.03 - 1.12), HIV negatives (adj.
PRR = 1.19; 95% CI, 1.13 - 1.27), those not currently
married but previously married (adj.PRR = 1.10; 95% CI,
1.01 - 1.18), and among those who had spent more than
1 year in the community at the time of enrolment.
Compared to participants with less than 1 year of stay in
the community, adjusted PRRs of retention were 1.34
(95% CI 1.21 - 1.48) for 1 to 4 years, 1.57 (95% CI, 1.43 -
1.73) for 5 to 10 years, and 1.59 (95% CI, 1.44 - 1.76) for
more than 10 years of stay in fishing communities.
The overall HIV incidence rate was 3.39/100 pyar
(95% CI; 2.55 - 4.49). We estimated retention rates and
absolute HIV incidence rates by a combination of
selected risk factors so as to assess potential character-
istics that would maximize both retention and inci-
dence in case of targeted enrollment in efficacy studies
in this population (Table 2). HIV rates presented in
Table 2 are absolute risks that apply to specific groups
of single of combined risk factors and are not compara-
tive. Participants aged 30 or more years tended to have
Table 1 Proportions and prevalence proportion ratios (PPRs) of retention in a cohort of fishing communities around
Lake Victoria, Uganda
Retention rate (12 months) Prevalence proportion ratios of retention
% (No/enrolled) Crude Adjusted P- value
(95% CI) (95% CI)
All Participants 80.2 (1289/1607)
Sex
Male 79.6 (697/876) 1 (Ref) 1 (Ref)
Female 81.0 (592/731) 1.02 (0.97 - 1.07) 1.05 (0.99 - 1.11) 0.074
Age at enrolment (years)
18-24 72.8 (366/503)†† 1 (Ref) 1 (Ref)
25-29 79.8 (328/411) 1.10 (1.02 - 1.18) 1.00 (0.93 - 1.07) 0.933
30-39 86.1 (432/502) 1.18 (1.11 - 1.26) 1.04 (0.97 - 1.11) 0.273
40-49 85.3 (163/191) 1.17 (1.08 - 1.27) 1.00 (0.92 - 1.09) 0.953
Highest Education level*
None 80.4 (90/112) 1 (Ref) -
Primary 79.4 (734/924) 0.99 (0.90 - 1.09) -
Post primary 81.3 (462/568) 1.01 (0.92 - 1.12) -
Religion
Pentecostal/Evangelical 82.9 (131/158) 1 (Ref) -
Roman Catholic 81.6 (507/621) 0.98 (0.91 - 1.07) -
Protestant/Anglican 76.7 (342/446) 0.92 (0.85 - 1.01) -
Moslem 80.4 (263/327) 0.97 (0.89 - 1.06) -
Other¶ 83.6 (46/55) 1.01 (0.88 - 1.16) -
Ethnicity/tribe
Non-Muganda 76.9 (681/885)†† 1 (Ref) 1 (Ref)
Muganda 84.2 (608/722) 1.09 (1.04 - 1.15) 1.06 (1.01 - 1.11) 0.021
Occupation
Fishing/Fishing related 80.5 (648/805) 1 (Ref) 1 (Ref)
Trade/Business 81.2 (135/165) 1.02 (0.94 - 1.10) 0.96 (0.89 - 1.04) 0.382
Bar/Lodge/Restaurant 75.9 (123/162) 0.94 (0.86 - 1.03) 0.95 (0.87 - 1.05) 0.326
Farming 86.2 (75/87) 1.07 (0.98 - 1.17) 1.00 (0.92 - 1.10) 0.870
Housewife 78.3 (101/129) 0.97 (0.88 - 1.07) 0.93 (0.84 - 1.03) 0.194
Others† 79.9 (207/259) 0.99 (0.92 - 1.06) 0.98 (0.92 - 1.05) 0.667
Marital status
Never married 70.2 (214/305)†† 1 (Ref) 1 (Ref)
Not currently married 79.7 (263/330) 1.14 (1.04 - 1.24) 1.03 (0.93 - 1.13) 0.570
Married monogamous 83.3 (575/690) 1.19 (1.09 - 1.29) 1.08 (0.99 - 1.18) 0.064
Married polygamous 80.4 (237/282) 1.20 (1.09 - 1.31) 1.07 (0.97 - 1.17) 0.169
Duration in community (years)
Less than 1 58.3 (175/300) 1 (Ref) 1 (Ref)
1 to 4 77.6 (464/598) 1.33 (1.20 - 1.48) 1.31 (1.17 - 1.45) <0.0001
5 to 10 90.9 (440/484) 1.56 (1.41 - 1.72) 1.50 (1.35 - 1.66) <0.0001
More than 10 93.3 (210/225) 1.60 (1.44 - 1.77) 1.54 (1.39 - 1.72) <0.0001
*3 missing education, ¶Seventh Day Advent/Traditionist †Construction/Mechanic/Government/Clerical , ††Statistically significant at p < 0.05 during
bivariate analysis.
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Table 2 Retention rates and absolute HIV incidence rates by selected risk factors
Characteristic Retention at 12 months Absolute HIV risk
Percent (Followed/enrolled) Rate/100 pyar (95% CI)
All participants 76.9% (1685/2191) 3.39 (2.55 - 4.49)
Age at enrolment (years)
30+ 81.5% (822/1009) 2.45 (1.50 - 4.00)
25-29 76.7% (434/566) 4.77 (2.96 - 7.67)
18-24 69.6% (429/616) 3.68 (2.22 - 6.11)
Age and fishing occupation
30+ and involved in fishing 81.3% (414/509) 3.26 (1.80 - 5.90)
25-29 and involved in fishing 78.5% (226/288) 4.61 (2.40 - 8.85)
18-24 and involved in fishing 73.4% (177/241) 4.02 (1.92 - 8.43)
Age and alcohol drinking
30+ and drinks alcohol 79.6% (460/578) 3.34 (1.89 - 5.89)
25-29 and drinks alcohol 78.1% (234/311) 7.67 (4.62 - 12.7)
18-24 and drinks alcohol 67.5% (183/271) 5.67 (3.14 - 10.2)
Age, fishing and alcohol drinking
30+, fishing and alcohol use 79.9% (243/304) 3.57 (1.70 - 7.49)
25-29, fishing and alcohol use 83.1% (138/166) 6.77 (3.39 - 13.5)
18-24, fishing and alcohol use 72.6% (85/117) 4.99 (1.87 - 13.3)
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were engaged in actual fishing and or alcohol drinking.
In this age-group however, the HIV incidence rate
ranges between 2.45 and 3.57 per 100 pyar. For every
combination of risk factors, HIV incidence was highest
in age group of 25–29 years, ranging between 4.61 and
7.67/100 pyar. In this same age group, retention rates
between 78.5 - 83.1% were observed. For every com-
bination of risk factors, the lowest retention rate was
among 18–24 year old participants.Willingness to participate in future HIV vaccine trials
Overall WTP was 89.1% (1953/2191) and was higher in
men than women (91.2% vs 87.3%, p = 0.004) and
among island communities relative to lakeshore ones
(90.4% vs 85.8%, p = 0.004) (data not shown). We
assessed the factors associated with lack of WTP
(unwillingness to participate in future vaccine trials). As
shown in Table 3, adjusted predictors of lack of WTP were
sex, duration of stay in community and alcohol consump-
tion. Lack of WTP was significantly higher among women
than men [adj.OR = 1.51 (95% CI, 1.14- 2.00)] and among
participants who had stayed in fishing communities for 10
or more years relative to those with less than one year
[adj.OR = 1.78 (95% CI, 1.11 - 2.88)]. However, particpants
who drink alcohol were less likely to lack WTP than non-
drinkers [adj.OR = 0.74 (95% CI, 0.56 - 0.98)] i.e., alcohol
drinkers were more willing to participate.Discussion
Our assessment indicates that fishing communities
around Lake Victoria, Uganda, are potential populations
for future HIV vaccine efficacy studies. In these commu-
nities we found an overall HIV-1 incidence rate of 3.39/
100 pyar, a retention rate of 77%, and WTP of 89.3%.
The overall incidence rate in this fishing community
general population is about 4–5 times higher than that
estimated for the national general population of Uganda
[28] and 3 times higher than the rate observed in some
long term cohorts in Uganda [40,41]. Some sub-groups
in these fishing communities have incidence rates as high
as 7.7/100 pyar [27]. Other population groups in Uganda
with comparable levels of HIV incidence include female sex
workers and long distance truck drivers [23,25,26] which
are highly selected and gender skewed groups, making it
difficult to generalize findings from these populations.
Contrary to the belief that fisher folk are difficult to
retain given their mobile nature, we were able to retain
77% at a 12 month inter-survey interval using passive
follow up. This result is very encouraging in that with
active follow up at shorter intervals such as those in a
vaccine efficacy trials, retention rate is expected to be
much higher than that observed in this study. Retention
was higher among participants who had stayed for more
than one year in the communities which may imply that
recent migrants tend to be less stable and may cause
challenges in follow up studies. The retention rate we
found in this general population of fishing communities
Table 3 Multivariable analysis of factors associated with lack of willingness to participate (WTP) in hypothetical HIV
vaccine trials
WTP Odds ratio of lack of WTP
Yes No Crude Adjusted P- value
No. (%) No. (%) (95% CI) (95% CI)
All Participants 1953 (89.1) 238 (10.9)
Sex
Male 1007 (91.1) 99 (8.9)†† 1 (Ref) 1 (Ref)
Female 946 (87.2) 139 (12.8) 1.49 (1.14 - 1.96) 1.51 (1.14 - 2.00) 0.004††
Age at enrolment (years)
30+ 896 (88.8) 113 (11.2) 1 (Ref) -
25-29 509 (89.9) 57 (10.1) 0.89 (0.63 - 1.24) -
18-24 548 (89.0) 68 (11.0) 0.98 (0.71 - 1.35) -
Religion
Pentecostal/Evangelical 169 (85.8) 28 (14.2)†† 1 (Ref) -
Roman Catholic 801 (90.0) 89 (10.0) 0.67 (0.42 - 1.06) -
Protestant/Anglican 546 (91.0) 54 (9.0) 0.60 (0.37 - 0.97) -
Moslem 361 (85.8) 60 (14.2) 1.00 (0.62 - 1.63) -
Other¶ 76 (91.6) 7 (8.4) 0.55 (0.23 - 1.33) -
Ethnicity/tribe
Non-Muganda 1080 (90.2) 117 (9.8) 1 (Ref) -
Muganda 873 (87.8) 121 (12.2) 1.28 (0.98 - 1.67) -
Occupation
Fishing/Fishing related 947 (91.2) 91 (8.8) 1 (Ref) -
Trade/Business 196 (87.9) 27 (12.1) 1.43 (0.91 - 2.26) -
Bar/Lodge/Restaurant 225 (87.6) 32 (12.4) 1.48 (0.96 - 2.27) -
Farming 114 (87.7) 16 (12.3) 1.46 (0.83 - 2.57) -
Othersᵵ 309 (87.5) 44 (12.5) 1.48 (1.01 - 2.17) -
Housewife 162 (85.3) 28 (14.7) 1.79 (1.14 - 2.83) -
Marital status
Married monogamous 819 (88.7) 104 (11.3) 1 (Ref)
Married polygamous 378 (89.4) 45 (10.6) 0.94 (0.65 - 1.36) -
Not currently married 450 (89.1) 55 (10.9) 0.96 (0.68 - 1.36)
Never married 306 (90.0) 34 (10.0) 0.87 (0.58 - 1.32) -
Duration in community (years)
Less than 1 357 (90.6) 37 (9.4)† 1 (Ref) 1 (Ref)
1 to 4 737 (89.6) 86 (10.4) 1.12 (0.75 - 1.69) 1.17 (0.78 - 1.77) 0.43
5 to 10 597 (89.2) 72 (10.8) 1.16 (0.77 - 1.77) 1.26 (0.83 - 1.93) 0.28
More than 10 262 (85.9) 43 (14.1) 1.58 (0.99 - 2.53) 1.78 (1.11 - 2.88) 0.018
Alcohol consumption
No 1104 (87.9) 152 (12.1)†† 1 (Ref) 1 (Ref)
Yes 849 (90.8) 86 (9.2) 0.70 (0.53 - 0.91) 0.74 (0.56 - 0.98) 0.04
¶Seventh Day Adventist/Traditional, ††Statistically significant at p < 0.05, †Borderline statistical significance at p < 0.05, ᵵConstruction/Mechanic/Government/Clerical.
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screened for high risk behaviours (76%) [24] and in other
population-based studies in Uganda [42,43]. In a com-
bined analysis of retention and incidence ratesparticipants aged 30 or more years had retention
rates ~80% with incidence rates ranging between 2.45
and 3.57 per 100 pyar while those aged 25–29 years had
the highest incidence rates (4.61 - 7.67/100 pyar) and
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lowest among young adults aged 18–24 years. This finding
appears to indicate that among fishing communities
around Lake Victoria, Uganda, maximization of both HIV
incidence and retention occurs among participants aged
25–29 years. In actual vaccine efficacy trials, efficient re-
cruitment and retention of large numbers of participants
is crucial in for the success of the study [12,13]. Our ob-
served retention rate of 77% could be improved by
methods such as frequent participant contact and active
tracing, shorter follow up intervals, and use of mobile tele-
phone technology which have improved retention in other
high risk and marginalized population groups [44,45].
However, given the unique characteristics of fishing com-
munities it would be prudent to evaluate the effectiveness
of those strategies in enhancing retention before adopting
them in actual trials.
Although WTP assessed hypothetically does not ne-
cessarily reflect levels participation in a real trial [46],
we found that only 10.9% of fisherfolk expressed lack of
willingness to participate in future HIV vaccine trials.
Lack of WTP was significantly higher among women
and folks with 10 or more years of stay in communities.
A similar study in Masaka district, southern Uganda,
also found higher levels of lack of WTP among women
than men. In that study the requirement to delay preg-
nancy during the trial and shortly thereafter was associ-
ated with lower levels of WTP [31]. Since both women
and men will be needed to participate in future HIV
vaccine efficacy trials, it is important to address issues
that may lead to women's unwillingness to participate
in these trials. We also found that lack of WTP was sig-
nificantly lower among alcohol drinkers yet alcohol
drinking is one of major risk factors for HIV infection
in this population. This finding indicates that it may
not be difficult to recruit "high risk" fisherfolk in future
vaccine efficacy trials. However, lack of WTP was sig-
nificantly higher in person who had stayed for more
than 10 years in fishing communities yet retention was
much better in same group. At this time we do not
know the reasons for this discrepancy but plans to in-
vestigate it are underway.
The strength of this study is that it was conducted in a
randomly selected general population of fishing commu-
nities. We note that the study is not without limitations.
First, a long inter-survey period of 12 months does not
represent the shorter follow up intervals typically seen in
the early period of vaccine trials. Second, the hypothet-
ical assessment of WTP does not necessarily reflect ac-
tual willingness observed in real vaccine trials [46].
Third, retention rates were assessed at one follow up
visit (due to the design of the study) and as such repre-
sent a cross-sectional assessment at the one follow up
visit.Conclusions
The finding of high HIV incidence, good retention rates,
and high WTP, indicates that fishing communities are po-
tential populations for HIV prevention efficacy trials in-
cluding vaccines and combination interventions.
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